Parabilis to present updated zolucatetide data in desmoid tumors at ESMO 2026

Parabilis Medicines, Inc.

Updated Phase 1/2 zolucatetide data in desmoid tumors to be presented at ESMO Congress 2026 in Madrid.
Oral presentation scheduled Oct 24, 2:45pm CEST in sarcoma-focused Proffered Paper session.
Company updates guidance to reflect intention to present data; no numbers disclosed yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.